The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Dupilumab: First Global Approval
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 10×
“In each of the three trials, adult patients (aged C18 years) with moderate-to-severe atopic dermatitis not adequately controlled by topical medication(s) were randomized (1:1:1 in SOLO 1 and SOLO 2; 3:1:3 in CHRONOS) to receive subcutaneous dupilumab 300 mg once weekly, dupilumab 300 mg once every 2 weeks or placebo […”
BackgroundResultInfluentialBachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794 · cited 6×
“The efficacy of subcutaneous dupilumab in the treatment of nasal polyposis has been investigated in a randomized, double-blind, placebo-controlled, proof-of-concept phase II trial in adult patients (n = 60) with chronic sinusitis and nasal polyposis refractory to intranasal corticosteroids (NCT01920893) [10].”
BackgroundInfluential
Cited by
De Pessemier, B., Grine, L., Debaere, M., Maes, A., Paetzold, B., & Callewaert, C. (2021) · Microorganisms · doi:10.3390/microorganisms9020353 · Cited by 628
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Kabashima, K., Matsumura, T., Komazaki, H., & Kawashima, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917006 · Cited by 361
Recent advances in understanding the role of IL-4 signaling
Keegan, A. D., Leonard, W. J., & Zhu, J. (2021) · Faculty Reviews · doi:10.12703/r/10-71 · Cited by 154
Wang, C., Kraus, C. N., Patel, K. G., Ganesan, A. K., & Grando, S. A. (2020) · International Journal of Dermatology · doi:10.1111/ijd.14573 · Cited by 78
Metadata
- Authors
- Shirley, M.
- Venue
- Drugs
- Published
- 2017-05-25
- Volume
- 77
- Issue
- 10
- Pages
- 1115-1121
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2620124785
- Cited by
- 175
- References
- 2
- FWCI
- 18.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dupilumab: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-017-0768-3
- The paper
- Shirley, M. (2017). Dupilumab: First Global Approval. Drugs. https://doi.org/10.1007/s40265-017-0768-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.